Myths vs facts: ApoB and menopause

ApoB (apolipoprotein B) is a direct measure of the number of atherogenic particles (LDL, VLDL, IDL) and is considered a more precise risk marker than LDL cholesterol alone. Myth: 'After menopause, only LDL rises; ApoB stays the same.' Fact: The estrogen decline in menopause leads to an increase in small, dense LDL particles, which are particularly atherogenic. Since each such particle carries one ApoB molecule, ApoB often rises more than LDL-C. Another myth: 'ApoB is only relevant for men.' Fact: Women have lower ApoB before menopause, but after menopause the risk converges – ApoB is a strong predictor in both sexes. Myth: 'A normal LDL level rules out high risk.' Fact: With normal LDL, ApoB can be elevated (discordant hyperlipidemia), especially in metabolic syndrome or insulin resistance, which become more common during menopause. Evidence comes from large prospective studies and meta-analyses (e.g., Emerging Risk Factors Collaboration). Caveat: ApoB alone does not replace comprehensive risk stratification (including Lp(a), hsCRP, blood pressure, family history). A physician should interpret values in context. Evidence: human-moderate (strong observational data, but no RCTs proving ApoB as sole therapeutic target).